Ahmed Hosny Hassan

Dr. Ahmed Hosny Hassan

Clinical pharmacy department, Mansoura University Hospital, Al Manşūrah, Ad Daqahlīyah, Egypt
Clinical Pharmacist and researcher

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Journal of Clinical Virology Plus
Verified
Journal Article
Open access
SHSahar K. Hegazy
Sahar K. Hegazy
STSamar Tharwat
Samar Tharwat
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
Corona Virus disease - 2019 (COVID-19) disease induces scientific research to find a control to this pandemic from 2020 year up to now. Recently, various advances in pharmacotherapy against COVID-19 have emerged. To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients This study is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are prescribed by lectures on chest diseases, faculty of medicine-Mansoura University. The duration of the study is about six months after ethical approval. 265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048–3051(Antibodies cocktail (casirivimab and imdevimab)), group (B) received remdesivir, and group (C) received favipravir. Casirivimab and imdevimab achieve less 28-day mortality rate, and less mortality at hospital discharge than Remdesivir, and Favipravir. From all of these results, it is concluded that Group A (Casirivimab & imdevimab) achieves more favorable outcomes than B (Remdesivir) & C (Favipravir) intervention groups. NCT05502081, 16/08/2022, Clinicaltrials.gov

16 September 2023 in World Journal of Clinical Cases
Verified
Journal Article
Open access
SHSahar Kmal Hegazy
Sahar Kmal Hegazy
STSamar Tharwat
Samar Tharwat
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
Coronavirus disease 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021-year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipiravir. To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing the need for invasive mechanical ventilation (IMV). 265 COVID-19 polymerase chain reaction confirmed patients with indication for antiviral therapy were included in this study and were divided into 3 groups (1: 2: 2): Group A: REGN3048-3051 antibodies cocktail (casirivimab and imdevimab), group B: Remdesivir, group C: Favipiravir. The study design is a single-blind non-randomized controlled trial Mansoura University Hospital owns the study’s drugs. The duration of the study was about 6 mo after ethical approval. Casirivimab and imdevimab achieve less need for O2 therapy and IMV, with less duration of this need than remdesivir and favipiravir. Group A (casirivimab and imdevimab) achieve better clinical outcomes than groups B (remdesivir) and C (favipiravir) intervention groups.

1 January 2023 in Open Medicine
Verified
Journal Article
Open access
PDF file
SHSahar K. Hegazy
Sahar K. Hegazy
STSamar Tharwat
Samar Tharwat
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral therapy against COVID-19 includes remdesivir and favipiravir. The objectives were to compare progression and multi-organ function of hospitalized COVID-19 patients between these three antiviral groups. 265 COVID-19 hospitalized patients were included in this study and were divided into 3 groups (1:2:2), respectively, Group (A): casirivimab and imdevimab, group (B): remdesivir, and group (C): favipiravir. The design of the study is a single blind non-randomized controlled trial. This study is a phase IV clinical trial (post-marketing study). The duration of the study was about 6 months after receiving the ethical approval. Casirivimab and imdevimab achieved less case progression as presented by lower World Health Organization scale (P < 0.05 in comparing group A with B and C) and better multi-organ functions as presented by lower Sequential Organ Function Assessment score (P < 0.05 in comparing group A with B and C) than remdesivir and favipiravir. From all these results, it is concluded that Group A (casirivimab and imdevimab) produces better outcomes than B (remdesivir) and C (favipiravir) intervention groups.

22 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
SHSahar K. Hegazy
Sahar K. Hegazy
SRSamar T. Radwan
Samar T. Radwan
Introduction Corona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir. Aim of Study To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19 To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effects Patients and Population 265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is included in this study and will be divided into 3 groups (1:2:2): Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)) group B: Remdesivir group C: Favipravir Methods Study design is single blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH), and prescribed by chest diseases lectures of faculty of medicine-Mansoura University. The duration of study is about 6 months after ethical approval. Results and discussion Casirivimab and imedivimab achieves less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O2 therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower World Health Organization (WHO) scale and better multi-organ functions as presented by lower Sequential Organ Function Assessment (SOFA) score than Remdesivir and Favipravir. Conclusion From all of these results, it is concluded that Group A (Casirivimab & imedivimab) has more favorable clinical outcomes than B (remdesivir) & C (favipravir) intervention groups.

8 May 2024 in Life Science Research Communications
Verified
Journal Article
Open access
PDF file
SHSahar Kmal Hegazy
Sahar Kmal Hegazy
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
Objectives The coronavirus disease of 2019 (COVID-19) disease advances science’s ability to address this catastrophe. Additionally, there have been numerous therapeutic advances against COVID-19. Antibody combination against COVID-19, casirivimab and imdevimab, is used in antiviral therapy. Remdesivir and Favipiravir are the two antiviral medications typically used to treat COVID-19. The aim is to compare the effect of remdesivir, favipiravir, and casirivimab and imdevimab on the duration of hospital and ICU stay of COVID-19 patients. Materials and Methods In this study, 265 COVID-19 patients with Polymerase Chain Reaction (PCR) confirmation and indications for antiviral medication were allocated into one of three groups in a ratio of (2:2:1) Remdesivir (REM group); Favipiravir (FAV group), and casirivimab and imdevimab (REG group) respectively. Single-blind non-Randomized Controlled Trial (non-RCT) was the study design. The study’s medication is owned by Mansoura University Hospital (MUH). Following ethical permission. The duration of the study was six months from November 2021 to March 2022. Results Casirivimab and imdevimab decrease hospital and ICU stay than favipiravir and remdesivir. Conclusion Although casirivimab and imdevimab lack activity against the omicron variant of COVID-19, they cause better clinical parameters than the standard antiviral drugs.

14 October 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
SHSahar K. Hegazy
Sahar K. Hegazy
AHAhmed Hosny Hassan
Ahmed Hosny Hassan
Background: The Coronavirus Disease of 2019 (COVID-19) pandemic motivated research efforts to address this catastrophe from the beginning of 2020 to the present. The year 2021 is coming to an end, and several developments in pharmacotherapy for COVID-19 have occurred. In terms of antiviral therapy, monoclonal antibody combinations have become one type of COVID-19 immunotherapy. Remdesivir and favipiravir are two antiviral medications typically used to treat COVID-19. Paxlovid (nirmatrelvir plus ritonavir) and molnupiravir are other antiviral agents used in COVID-19. The purpose of this study was to compare the effects of combinations of antibodies (casirivimab and imdevimab), remdesivir, and favipiravir on COVID-19 swab results in hospitalized patients with COVID-19 at discharge. Methods: This research is a phase IV non-randomized controlled trial (< 300 patients as sample size) with no comparison to placebo. In this study, 265 COVID-19 patients confirmed by polymerase chain reaction (PCR) and indications for antiviral medication were non-randomized into three groups at a ratio of (1:2:2): REGN3048-3051 (group A), remdesivir (group B), and favipiravir (group C). A nonrandomized single-blind controlled study design was used. The study's medication was provided by the Hospital of Mansoura University. Following ethical approval, the study was conducted for approximately 6 months. Results: Compared to remdesivir and favipiravir, casirivimab and imdevimab cause less hepatotoxicity, less renal impairment, and more negative swab results at discharge. The three tested antivirals also had no significant adverse effects. All three antivirals are considered safe based on these findings. Conclusion: Compared with remdesivir and favipiravir, casirivimab and imdevimab result in better clinical outcomes. All three antivirals are safe and have no significant toxicity. Trial registration: Clinicaltrials.gov, NCT05502081, 16/08/2022.